HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem Q1 2007

This article was originally published in The Rose Sheet

Executive Summary

Twenty-percent revenue growth for the first quarter of fiscal year 2007, to $100.8 million, was driven by sales of the five products - including anti-cavity mouthwash brand ACT - acquired from Johnson & Johnson in January for $410 million (1"The Rose Sheet" Jan. 8, 2007, In Brief). "We did not have time to do anything dramatically new, but since we bought very solid brands, they performed very solidly," CEO Zan Guerry remarked during March 22 earnings call. Results do not reflect the full impact of advertising Chattem launched in February, he added. Firm's Gold Bond and Icy Hot franchises also contributed to the quarter's success, their sales growing 27% and 23%, respectively, Chattem reports. Like last quarter, increases were offset by a reduction in sales of Icy Hot Pro-Therapy from launch levels in the first quarter of FY 2006 (2"The Rose Sheet" Feb. 19, 2007, p. 11)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel